Phota of Vivek Subbiah taken from eurekalert.org
Apr 15, 2024, 12:30
Vivek Subbiah: Using ePROs to prompt direct patient trial invitations
Vivek Subbiah shared a post on X:
“Published in JAMA Oncology.
Using ePROs to prompt direct patient trial invitations resulted in greater enrollment to a symptom-intervention trial than standard of care physician-based referral.”
Read further.
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56